1. Interstitial granulomatous dermatitis following tocilizumab, a paradoxical reaction?
- Author
-
Montse Salleras-Redonnet, Maribel Iglesias-Sancho, Arcadi Altemir, Maite Fernández-Figueras, Luis Novoa-Lamazares, and María de los Ángeles Sola-Casas
- Subjects
Adult ,medicine.medical_specialty ,chemical and pharmacologic phenomena ,Dermatitis ,Dermatology ,Disease ,Antibodies, Monoclonal, Humanized ,Immunoglobulin D ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,Granuloma Annulare ,0302 clinical medicine ,Tocilizumab ,hemic and lymphatic diseases ,Medicine ,Humans ,Granuloma annulare ,Interstitial granulomatous dermatitis ,Granuloma ,biology ,business.industry ,Paradoxical reaction ,General Medicine ,medicine.disease ,Giant cell arteritis ,chemistry ,030220 oncology & carcinogenesis ,biology.protein ,Sarcoidosis ,business - Abstract
Interstitial granulomatous dermatitis (IGD) is a rare dermatosis generally seen in the setting of rheumatic diseases, but also hematological disorders, internal malignances, infections, or drug induced. Herein, we report an exceptional case of an IGD with a clear chronological association with tocilizumab onset and cessation in a patient with adult-onset Still's disease. We review the granulomatous cutaneous reactions so far reported with this novel therapy: sarcoidosis, granuloma annulare, and IGD. Tocilizumab is a humanized anti-interleukin 6 receptor monoclonal antibody useful for the treatment of various systemic inflammatory disorders. Lately, it has found useful also for granulomatous diseases such as giant cell arteritis and even a promising response in IGD. Therefore, we believe our case adds the possibility of an IGD presenting as a paradoxical reaction.
- Published
- 2020